These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35108650)

  • 21. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
    Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
    Elife; 2020 Mar; 9():. PubMed ID: 32151314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of the germline sequence on the thermodynamic stability and fibrillogenicity of human lambda 6 light chains.
    del Pozo Yauner L; Ortiz E; Sánchez R; Sánchez-López R; Güereca L; Murphy CL; Allen A; Wall JS; Fernández-Velasco DA; Solomon A; Becerril B
    Proteins; 2008 Aug; 72(2):684-92. PubMed ID: 18260098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AL amyloidosis with a localized B cell neoplasia.
    Stuhlmann-Laeisz C; Schönland SO; Hegenbart U; Oschlies I; Baumgart JV; Krüger S; Röcken C
    Virchows Arch; 2019 Mar; 474(3):353-363. PubMed ID: 30680453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis.
    Karimi-Farsijani S; Pfeiffer PB; Banerjee S; Baur J; Kuhn L; Kupfer N; Hegenbart U; Schönland SO; Wiese S; Haupt C; Schmidt M; Fändrich M
    Nat Commun; 2024 Jun; 15(1):5121. PubMed ID: 38879609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.
    Blancas-Mejía LM; Hammernik J; Marin-Argany M; Ramirez-Alvarado M
    J Biol Chem; 2015 Feb; 290(8):4953-4965. PubMed ID: 25538238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanistic insights into the aggregation pathway of the patient-derived immunoglobulin light chain variable domain protein FOR005.
    Pradhan T; Sarkar R; Meighen-Berger KM; Feige MJ; Zacharias M; Reif B
    Nat Commun; 2023 Jun; 14(1):3755. PubMed ID: 37353525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
    Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
    J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An autopsy case of amyloid tubulopathy exhibiting characteristic spheroid-type deposition.
    Ichimata S; Hata Y; Abe R; Yoshinaga T; Katoh N; Kametani F; Yazaki M; Sekijima Y; Ehara T; Nishida N
    Virchows Arch; 2020 Jul; 477(1):157-163. PubMed ID: 31932919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Formation of amyloid fibers by monomeric light chain variable domains.
    Brumshtein B; Esswein SR; Landau M; Ryan CM; Whitelegge JP; Phillips ML; Cascio D; Sawaya MR; Eisenberg DS
    J Biol Chem; 2014 Oct; 289(40):27513-25. PubMed ID: 25138218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigallocatechin-3-gallate preferentially induces aggregation of amyloidogenic immunoglobulin light chains.
    Hora M; Carballo-Pacheco M; Weber B; Morris VK; Wittkopf A; Buchner J; Strodel B; Reif B
    Sci Rep; 2017 Jan; 7():41515. PubMed ID: 28128355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis.
    Clos AL; Lasagna-Reeves CA; Castillo-Carranza DL; Sengupta U; Jackson GR; Kelly B; Beachkofsky TM; Kayed R
    Br J Dermatol; 2011 Dec; 165(6):1349-54. PubMed ID: 21729025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methods to study the structure of misfolded protein states in systemic amyloidosis.
    Fändrich M; Schmidt M
    Biochem Soc Trans; 2021 Apr; 49(2):977-985. PubMed ID: 33929491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis.
    Wang J; Li J; Zhong L
    Blood Rev; 2024 Jul; 66():101207. PubMed ID: 38692939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical and immunochemical study of amyloid in liver affected by systemic Alambda amyloidosis with antibodies against three different regions of immunoglobulin lambda light chain.
    Kiyama M; Hoshii Y; Cui D; Kawano H; Kanda T; Ishihara T
    Pathol Int; 2007 Jun; 57(6):343-50. PubMed ID: 17539965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.
    Andrich K; Hegenbart U; Kimmich C; Kedia N; Bergen HR; Schönland S; Wanker E; Bieschke J
    J Biol Chem; 2017 Feb; 292(6):2328-2344. PubMed ID: 28031465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Cryo-EM STRUCTURE of Renal Amyloid Fibril Suggests Structurally Homogeneous Multiorgan Aggregation in AL Amyloidosis.
    Puri S; Schulte T; Chaves-Sanjuan A; Mazzini G; Caminito S; Pappone C; Anastasia L; Milani P; Merlini G; Bolognesi M; Nuvolone M; Palladini G; Ricagno S
    J Mol Biol; 2023 Sep; 435(18):168215. PubMed ID: 37516426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
    Koike H; Katsuno M
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis.
    Morgan GJ
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34208058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dissection of the amyloid formation pathway in AL amyloidosis.
    Kazman P; Absmeier RM; Engelhardt H; Buchner J
    Nat Commun; 2021 Nov; 12(1):6516. PubMed ID: 34764275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lambda II immunoglobulin light chain protein in primary localized rectal amyloidosis.
    Zaky ZS; Liepnieks JJ; Rex DK; Cummings OW; Benson MD
    Amyloid; 2007 Dec; 14(4):299-304. PubMed ID: 17968691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.